SecSonar.com

Agios Pharmaceuticals, Inc. (AGIO)

Agios Pharmaceuticals, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Agios Pharmaceuticals, Inc. (AGIO) is a Biotechnology company based in US with a market capitalization of $1.8B. Revenue grew 48.0% year-over-year and free cash flow was negative at -$377.3M. This page tracks AGIO's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 486 employees · IPO Jul 24, 2013

Valuation

Valuation & price

$28.23 · as of May 15, 2026 · -38.0% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

1.49

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$45.49$35.03$24.57Jul 25Dec 25Jul 26Jul 7, 25$35.21Jul 9, 25$39.07Jul 11, 25$39.05Jul 15, 25$39.19Jul 17, 25$40.35Jul 21, 25$39.92Jul 23, 25$40.56Jul 25, 25$40.00Jul 29, 25$37.73Jul 31, 25$37.22Aug 4, 25$36.16Aug 6, 25$37.72Aug 11, 25$35.08Aug 13, 25$36.61Aug 15, 25$37.01Aug 19, 25$36.22Aug 21, 25$38.20Aug 25, 25$37.26Aug 27, 25$39.27Aug 29, 25$37.71Sep 3, 25$40.61Sep 5, 25$36.01Sep 9, 25$36.15Sep 11, 25$36.50Sep 16, 25$36.72Sep 18, 25$37.95Sep 22, 25$38.19Sep 24, 25$37.32Sep 26, 25$38.93Sep 30, 25$40.14Oct 2, 25$39.93Oct 6, 25$40.89Oct 8, 25$42.60Oct 10, 25$40.61Oct 14, 25$40.24Oct 16, 25$41.52Oct 21, 25$43.45Oct 23, 25$42.09Oct 27, 25$43.08Oct 29, 25$41.96Oct 31, 25$43.24Nov 4, 25$40.00Nov 6, 25$40.31Nov 10, 25$41.38Nov 12, 25$43.63Nov 14, 25$43.65Nov 18, 25$45.49Nov 20, 25$24.57Nov 25, 25$28.43Nov 28, 25$29.20Dec 2, 25$26.98Dec 4, 25$27.42Dec 8, 25$27.28Dec 10, 25$28.00Dec 12, 25$27.27Dec 16, 25$26.09Dec 18, 25$24.73Dec 22, 25$24.95Dec 24, 25$29.17Dec 29, 25$27.16Jan 2, 26$27.18Jan 6, 26$27.47Jan 8, 26$28.16Jan 12, 26$28.32Jan 14, 26$28.73Jan 16, 26$27.19Jan 21, 26$27.17Jan 23, 26$28.54Jan 27, 26$28.67Jan 29, 26$27.61Feb 2, 26$28.16Feb 4, 26$27.70Feb 9, 26$26.94Feb 11, 26$27.71Feb 13, 26$27.96Feb 18, 26$27.56Feb 20, 26$29.25Feb 24, 26$30.39Feb 26, 26$29.98Mar 2, 26$29.20Mar 4, 26$28.19Mar 6, 26$27.47Mar 10, 26$28.26Mar 12, 26$27.59Mar 17, 26$28.91Mar 19, 26$27.92Mar 23, 26$28.11Mar 25, 26$29.59Mar 27, 26$29.43Mar 31, 26$33.83Apr 2, 26$35.20Apr 7, 26$35.11Apr 9, 26$32.92Apr 13, 26$33.15Apr 15, 26$34.45Apr 17, 26$35.14Apr 22, 26$26.72Apr 24, 26$25.32Apr 28, 26$24.80Apr 30, 26$28.00May 4, 26$27.56May 6, 26$26.98May 8, 26$27.79May 12, 26$28.42May 14, 26$28.73May 18, 26$28.21May 20, 26$28.50May 22, 26$28.14May 28, 26$30.42Jun 1, 26$28.00Jun 3, 26$27.68Jun 5, 26$28.29Jun 9, 26$28.14Jun 11, 26$28.72Jun 15, 26$31.82Jun 17, 26$33.08Jun 22, 26$35.10Jun 24, 26$36.28Jun 26, 26$37.90Jul 2, 26$37.39
$22.3452-week range$45.49
Loading valuation history…

Fundamentals

Key fundamentals

$1.8B

Market cap

48.0%

Revenue growth (YoY)

78.7%

Gross margin

-$377.3M

Free cash flow (USD)

-$792.4M

Net debt

Net cash position

2.0%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$69.9MFY 2017$43.0MFY 2018$94.4MFY 2019$117.9MFY 2020$0.00FY 2021$0.00FY 2022$14.2MFY 2023$26.8MFY 2024$36.5MFY 2025$54.0M
$69.9M$54M

Free cash flow by year

2016 → 2025

FY 2016$28.6MFY 2017$-289.9MFY 2018$-311.4MFY 2019$-382.8MFY 2020$-304.9MFY 2021$-413.1MFY 2022$-314.4MFY 2023$-297.1MFY 2024$-391.5MFY 2025$-377.3M
$28.6M-$377.3M

Gross margin by year

2022 → 2025

FY 202288.0%FY 202364.6%FY 202488.6%FY 202578.7%
88.0%78.7%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

6

Insider sells · 90 days

Earnings

Last report: 10-Q filed Apr 29, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventAnnual Meeting OutcomesJun 18, 2026Filing
  • 8-K eventEarnings ReleaseApr 29, 2026Filing
  • Quarterly report10-Q FiledApr 29, 2026Filing
  • Insider sellInsider Sell $662K · 10b5-1 PlanGoff Brian · Director, Chief Executive Officer · $661.9KApr 6, 2026Filing
  • Insider sellInsider Sell $103K · 10b5-1 PlanViswanadhan Krishnan · Chief Corp Dev & Strategy · $102.7KApr 6, 2026Filing
  • Insider sellInsider Sell $113K · 10b5-1 PlanMilanova Tsveta · Chief Commercial Officer · $113.2KApr 6, 2026Filing
  • Insider sellInsider Sell $109K · 10b5-1 PlanJones Cecilia · Chief Financial Officer · $109KApr 6, 2026Filing
  • Insider sellInsider Sell $102K · 10b5-1 PlanGheuens Sarah · Chief Medical Officer · $102KApr 6, 2026Filing
  • Insider sellInsider Sell $114K · 10b5-1 PlanBurns James William · Chief Legal Officer · $113.8KApr 6, 2026Filing

Questions

Frequently asked questions

What is Agios Pharmaceuticals, Inc.'s market cap?

Agios Pharmaceuticals, Inc. (AGIO) has a market capitalization of $1.8B.

What is AGIO's P/E ratio?

A meaningful P/E ratio is not available for AGIO — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is AGIO's price-to-book (P/B) ratio?

AGIO trades at 1.49 times book value per share.

Are insiders buying AGIO stock?

SEC Form 4 filings show no open-market insider buys at Agios Pharmaceuticals, Inc. in the last 90 days (6 sells).

Same arena

Related companies in Biotechnology

NVAX

Novavax, Inc.

$1.8B

SNDX

Syndax Pharmaceuticals, Inc.

$1.7B

HRMY

Harmony Biosciences Holdings, Inc.

$1.8B

VCEL

Vericel Corporation

$1.7B

ZYME

Zymeworks Inc.

$1.9B

AAPG

Ascentage Pharma Group International

$1.9B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.